Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Nelotanserin for REM Sleep Behavior Disorder in Dementia with Lewy Bodies

Start: March 2016
End: May 2018
Enrollment: 60

What Is This Study About?

This Phase II clinical trial will evaluate the safety and efficacy of the experimental drug nelotanserin for the treatment of rapid eye movement (REM) sleep behavior disorder in people with dementia with Lewy bodies.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 85 Years

Must have:

  • Diagnosis of dementia with Lewy bodies
  • Presence of frequent REM sleep behavior episodes
  • Mini-Mental State Examination score of 18

Must NOT have:

  • Diagnosis of significant psychotic disorder, including but not limited to schizophrenia or bipolar disorder
  • REM sleep behavior disorder symptoms are secondary to or better accounted for by another medical condition, psychiatric disorder, or substance abuse
  • Current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic, or other medical disorder

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

For more information about this clinical trial, please contact Axovant Clinical Trials at 919-425-0709.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Axovant Sciences Ltd.

Source: ClinicalTrials.gov ID: NCT02708186

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health